WO2016100452A3 - Heteroaryl compounds and uses thereof - Google Patents

Heteroaryl compounds and uses thereof Download PDF

Info

Publication number
WO2016100452A3
WO2016100452A3 PCT/US2015/066002 US2015066002W WO2016100452A3 WO 2016100452 A3 WO2016100452 A3 WO 2016100452A3 US 2015066002 W US2015066002 W US 2015066002W WO 2016100452 A3 WO2016100452 A3 WO 2016100452A3
Authority
WO
WIPO (PCT)
Prior art keywords
heteroaryl compounds
erki
same
present
compounds
Prior art date
Application number
PCT/US2015/066002
Other languages
French (fr)
Other versions
WO2016100452A2 (en
Inventor
Lixin Qiao
Original Assignee
Celgene Avilomics Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Research, Inc. filed Critical Celgene Avilomics Research, Inc.
Publication of WO2016100452A2 publication Critical patent/WO2016100452A2/en
Publication of WO2016100452A3 publication Critical patent/WO2016100452A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides compounds which inhibit one or both of ERKI and ERK2 protein kinase activity, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of the present invention, and compositions thereof, are useful as inhibitors of one or both of ERKI and ERK2 and exhibit desirable characteristics for the same.
PCT/US2015/066002 2014-12-17 2015-12-16 Heteroaryl compounds and uses thereof WO2016100452A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093037P 2014-12-17 2014-12-17
US62/093,037 2014-12-17

Publications (2)

Publication Number Publication Date
WO2016100452A2 WO2016100452A2 (en) 2016-06-23
WO2016100452A3 true WO2016100452A3 (en) 2016-07-28

Family

ID=56127841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/066002 WO2016100452A2 (en) 2014-12-17 2015-12-16 Heteroaryl compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2016100452A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028923A1 (en) * 2010-07-28 2012-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8440822B2 (en) * 2007-04-18 2013-05-14 Michael Joseph Luzzio Sulfonyl amide derivatives for the treatment of abnormal cell growth
US20130158032A1 (en) * 2011-11-29 2013-06-20 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
US8735400B2 (en) * 2009-01-23 2014-05-27 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20140228322A1 (en) * 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440822B2 (en) * 2007-04-18 2013-05-14 Michael Joseph Luzzio Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8735400B2 (en) * 2009-01-23 2014-05-27 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20120028923A1 (en) * 2010-07-28 2012-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20130158032A1 (en) * 2011-11-29 2013-06-20 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
US20140228322A1 (en) * 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2016100452A2 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
MX2018009773A (en) Heteroaryl inhibitors of pad4.
EP4292594A3 (en) Inhibitors of ret
WO2018006074A3 (en) Compounds and methods for modulating rna function
EP3642182A4 (en) Compounds, compositions and methods for synthesis
WO2017050791A8 (en) New bicyclic compounds as dual atx/ca inhibitors
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
EP3672973A4 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2018005292A (en) Acc inhibitors and uses thereof.
MX2023008031A (en) Gcn2 inhibitors and uses thereof.
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
MX2018002986A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
WO2014011911A3 (en) Irak inhibitors and uses thereof
WO2015120062A8 (en) Therapeutic compounds and compositions
MX2018006632A (en) Bicyclic inhibitors of pad4.
WO2012021444A8 (en) Besylate salt of a btk inhibitor
WO2014011906A3 (en) Irak inhibitors and uses thereof
MX2016015565A (en) Certain protein kinase inhibitors.
IN2014DN10576A (en)
WO2013185082A3 (en) Inhibitors of bruton's tyrosine kinase
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15870951

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15870951

Country of ref document: EP

Kind code of ref document: A2